Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1991 Sep;74(1):153–159.

In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.

J L Benson 1, J Y Niederkorn 1
PMCID: PMC1384686  PMID: 1937568

Abstract

Immunological rejection of a highly immunogenic, syngeneic tumour (UV5C25) in the anterior chamber (AC) of BALB/c mice was analysed. Hosts developed systemic, tumour-specific cytotoxic T lymphocyte (CTL) activity (P less than 0.001) as well as systemic, tumour-specific delayed-type hypersensitivity (DTH) (P less than 0.001). Histopathological features of tumour rejection were consistent with that of a CTL-mediated process [i.e., piecemeal necrosis of individual tumour cells by tumour-infiltrating lymphocytes (TIL)]. There was no evidence of ischaemic necrosis, perivascular cuffing, infarction, or vascular damage, as expected of a DTH-mediated process. In an effort to selectively eliminate CTL or DTH effector cells and hence alter the pattern of tumour rejection, mice were treated with anti-CD8 or anti-CD4 antibodies, respectively. Elimination of either cell population not only eliminated both systemic CTL and DTH activity to this tumour, but also resulted in progressive tumour growth. Analysis of TIL from untreated tumour-bearing hosts demonstrated tumour-specific cytolysis (P less than 0.01) as well as the presence of DTH effector cells (P less than 0.01). These results indicate that while both DTH and CTL effector cells are present in the AC, only the latter are active in tumour resolution in the AC; DTH effectors are active systemically, but suppressed locally. Further, these data also suggest the requirement of a CD8+ cell population for the development of a systemic DTH response to this tumour.

Full text

PDF
153

Images in this article

157Figure 5
on p.157
157Figure 6
on p.157
158Figure 7
on p.158

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker C. F., Billingham R. E. Immunologically privileged sites. Adv Immunol. 1977;25:1–54. [PubMed] [Google Scholar]
  2. Cobbold S. P., Jayasuriya A., Nash A., Prospero T. D., Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. doi: 10.1038/312548a0. [DOI] [PubMed] [Google Scholar]
  3. Franklin R. M., Prendergast R. A. Primary rejection of skin allografts in the anterior chamber of the rabbit eye. J Immunol. 1970 Feb;104(2):463–469. [PubMed] [Google Scholar]
  4. Gocinski B. L., Tigelaar R. E. Roles of CD4+ and CD8+ T cells in murine contact sensitivity revealed by in vivo monoclonal antibody depletion. J Immunol. 1990 Jun 1;144(11):4121–4128. [PubMed] [Google Scholar]
  5. Granstein R. D., Staszewski R., Knisely T. L., Zeira E., Nazareno R., Latina M., Albert D. M. Aqueous humor contains transforming growth factor-beta and a small (less than 3500 daltons) inhibitor of thymocyte proliferation. J Immunol. 1990 Apr 15;144(8):3021–3027. [PubMed] [Google Scholar]
  6. Kaiser C. J., Ksander B. R., Streilein J. W. Inhibition of lymphocyte proliferation by aqueous humor. Reg Immunol. 1989 Jan-Feb;2(1):42–49. [PubMed] [Google Scholar]
  7. Kaplan H. J., Streilein J. W. Immune response to immunization via the anterior chamber of the eye. II. An analysis of F1 lymphocyte-induced immune deviation. J Immunol. 1978 Mar;120(3):689–693. [PubMed] [Google Scholar]
  8. Knisely T. L., Luckenbach M. W., Fischer B. J., Niederkorn J. Y. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol. 1987 Jun 15;138(12):4515–4523. [PubMed] [Google Scholar]
  9. Knisely T. L., Niederkorn J. Y. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. Cancer Immunol Immunother. 1990;30(6):323–330. doi: 10.1007/BF01786881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. McAllister C. G., Wiggert B., Chader G. J., Kuwabara T., Gery I. Uveitogenic potential of lymphocytes sensitized to interphotoreceptor retinoid-binding protein. J Immunol. 1987 Mar 1;138(5):1416–1420. [PubMed] [Google Scholar]
  11. Moskophidis D., Fang L., Gossmann J., Drjupin R., Löhler J., Bruns M., Lehmann-Grube F. Virus-specific delayed-type hypersensitivity (DTH). Cells mediating lymphocytic choriomeningitis virus-specific DTH reaction in mice. J Immunol. 1990 Mar 1;144(5):1926–1934. [PubMed] [Google Scholar]
  12. Moskophidis D., Lehmann-Grube F. Virus-induced delayed-type hypersensitivity reaction is sequentially mediated by CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 1989 May;86(9):3291–3295. doi: 10.1073/pnas.86.9.3291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Niederkorn J. Y. Immune privilege and immune regulation in the eye. Adv Immunol. 1990;48:191–226. doi: 10.1016/s0065-2776(08)60755-5. [DOI] [PubMed] [Google Scholar]
  14. Niederkorn J. Y., Streilein J. W. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. J Immunol. 1983 Dec;131(6):2670–2674. [PubMed] [Google Scholar]
  15. Niederkorn J. Y., Streilein J. W. Analysis of antibody production induced by allogeneic tumor cells inoculated into the anterior chamber of the eye. Transplantation. 1982 Jun;33(6):573–577. doi: 10.1097/00007890-198206000-00001. [DOI] [PubMed] [Google Scholar]
  16. Niederkorn J. Y. Suppressed cellular immunity in mice harboring intraocular melanomas. Invest Ophthalmol Vis Sci. 1984 Apr;25(4):447–454. [PubMed] [Google Scholar]
  17. Niederkorn J., Streilein J. W., Shadduck J. A. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci. 1981 Mar;20(3):355–363. [PubMed] [Google Scholar]
  18. Raju S., Grogan J. B. Allograft implants in the anterior chamber of the eye of the rabbit. Early vascularization and sensitization of the host. Transplantation. 1969 Jun;7(6):475–483. doi: 10.1097/00007890-196906000-00004. [DOI] [PubMed] [Google Scholar]
  19. Streilein J. W. Immune regulation and the eye: a dangerous compromise. FASEB J. 1987 Sep;1(3):199–208. [PubMed] [Google Scholar]
  20. Streilein J. W., Niederkorn J. Y. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med. 1981 May 1;153(5):1058–1067. doi: 10.1084/jem.153.5.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Wilde D. B., Marrack P., Kappler J., Dialynas D. P., Fitch F. W. Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines. J Immunol. 1983 Nov;131(5):2178–2183. [PubMed] [Google Scholar]
  22. Williamson J. S., Streilein J. W. Impaired induction of delayed hypersensitivity following anterior chamber inoculation of alloantigens. Reg Immunol. 1988 Jul-Aug;1(1):15–23. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES